For the second quarter of 2026, analysts anticipate Quantum BioPharma will report a consensus revenue of $1.90 million and an earnings per share loss of $0.51, while the stock currently trades around $2.89 against a bullish $40.25 average analyst price target.
Investors are primarily focused on the resolution of the FDA clinical hold on the Lucid-MS (Lucid-21-302) Phase 2 trial, which was implemented in late May 2026. This regulatory obstacle has paused the lead multiple sclerosis program, shifting the near-term thesis toward regulatory-response quality and financing discipline. Furthermore, the market is tracking the company's liquidity position and the commercial rollout of its "unbuzzd" alcohol metabolism beverage under new leadership.